UAB researcher awarded first joint AACR- TNBC Foundation Career Development Award focused specifically on triple negative breast cancer.
Elevated PARP1 polymerase in HER2+ breast cancer may confer susceptibility to PARP inhibitor drugs.
Christopher Willey, M.D., Ph.D., receives a crucial ACS research grant to further his novel work on the MARCKS protein in relation to brain cancer.
Researchers at the University of Alabama at Birmingham have identified a strategy that highly aggressive brain tumor cells use to fuel their relentless expansion.
Yang’s research focuses on a new class of drug – PARP inhibitors – that interfere with a cancer cell’s ability to repair DNA damage, hastening cell death.